UTHealth received FDA approvalPositron Corporation, one of the leaders in molecular imaging healthcare, recently announced that the FDA approved the marketing of a new coronary flow reserve quantification software called cfrQuant.

At the University of Texas Health Science Center at Houston's Coronary Flow Reserve the quantification software was developed under the supervision of K. Lance Gould and the Weatherhead PET Imaging Center of the school. The approval was made possible through contributions of software segments from Positron Corporation.

"The introduction of CFR, as a routine non-invasive measurement used in conjunction with cardiac PET imaging, provides a clear differentiator when compared to competing technologies; justifying the expansion of patient indication selection and approval for reimbursement," said Joseph Oliverio, chief technology officer of Positron. "We believe cfrQuant will revolutionize the methodology of diagnosis and subsequent treatment of coronary disease, resulting in improved patient outcomes and cost savings within our healthcare system."

Positron will now distribute the new software to its current and future cardiac PET customers based in the United States.

With the approval of the new software, news also broke that UPS is focusing on the healthcare supply chain, giving customers more visibility and control over their products.
Share To:

Strategic Sourceror

Post A Comment:

0 comments so far,add yours